Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

塞库金单抗 医学 免疫原性 银屑病 银屑病性关节炎 单克隆抗体 药代动力学 单克隆 免疫学 内科学 抗体 胃肠病学 银屑病面积及严重程度指数
作者
Kristian Reich,Andrew Blauvelt,April Wang Armstrong,Richard G B Langley,A. de Vera,Frank Kolbinger,Sebastian Spindeldreher,M. Ren,Gerard J. M. Bruin
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:33 (9): 1733-1741 被引量:32
标识
DOI:10.1111/jdv.15637
摘要

BACKGROUND: Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, a key cytokine involved in psoriasis and psoriatic arthritis development, and has shown rapid and long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. Monoclonal antibody therapies may be associated with the production of treatment-emergent antidrug antibodies (TE-ADAs) that can affect drug pharmacokinetics, diminish clinical responses via inhibition of target binding or cause hypersensitivity reactions. Secukinumab exhibited minimal immunogenicity up to 52 weeks in patients with moderate-to-severe plaque psoriasis, as evidenced by TE-ADA in <1% patients. OBJECTIVE: To investigate the immunogenicity of secukinumab treatment up to 5 years in two phase 3 extension studies (NCT01640951 and NCT01365455) in patients with moderate-to-severe plaque psoriasis. METHODS: Immunogenicity was evaluated up to Week 268 (5 years). TE-ADAs were defined as positive antidrug antibody (ADA) signals detected in post-treatment samples from patients with negative baseline signals. Confirmed positive samples were further analysed for their neutralizing potential. RESULTS: In total, 1821 patients entered the extension studies. Among patients receiving secukinumab and evaluated for ADAs (n = 1636), 32 developed TE-ADA, which resulted in an incidence of new TE-ADA cases below 1% per year. Neutralizing antibodies were detected in 9/32 (28%) patients with TE-ADA. Half of ADA-positive cases were transient. Among pharmacokinetic samples measured at the times of immunogenicity determination (n = 9992), 544 (5.4%) had secukinumab concentrations higher than the drug tolerance level of 53.8 μg/mL. There was no effect of TE-ADA, including neutralizing antibodies, on efficacy, safety or pharmacokinetics of secukinumab. CONCLUSION: The yearly secukinumab immunogenicity incidence over 5 years of treatment was consistently below 1% in patients with moderate-to-severe plaque psoriasis. Any TE-ADAs, including neutralizing antibodies, were not associated with loss of secukinumab efficacy or with clinical concerns.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
arcidia发布了新的文献求助10
1秒前
ljx完成签到,获得积分10
1秒前
上官若男的应助被杨茜然采纳,获得10
1秒前
3秒前
科研通AI2S的应助被独特乘云采纳,获得10
3秒前
PYF8086完成签到,获得积分10
4秒前
4秒前
5秒前
6秒前
MSN发布了新的文献求助10
6秒前
研友_LMN2rn完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
空耳大师完成签到 ,获得积分10
8秒前
9秒前
9秒前
WHW发布了新的文献求助10
9秒前
tmj发布了新的文献求助10
9秒前
Cold完成签到,获得积分10
9秒前
Jensen完成签到,获得积分10
10秒前
nature发布了新的文献求助10
10秒前
xionggege完成签到,获得积分10
10秒前
xfy发布了新的文献求助200
10秒前
11秒前
11秒前
漆漆发布了新的文献求助10
11秒前
素人完成签到,获得积分10
11秒前
壶里有水给壶里有水的求助进行了留言
12秒前
arcidia完成签到,获得积分20
12秒前
GIN的应助被迷人的老黑采纳,获得20
12秒前
七颗茶香豆关注了科研通微信公众号
12秒前
萝卜完成签到 ,获得积分20
12秒前
13秒前
13秒前
13秒前
13秒前
heaven发布了新的文献求助10
14秒前
14秒前
英姑的应助被不敢说话采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156